B-intervention	0	9	Tamoxifen
O	10	13	for
O	14	24	prevention
O	25	27	of
O	28	34	breast
O	35	41	cancer
O	41	42	:
O	43	51	extended
O	52	56	long
O	56	57	-
O	57	61	term
O	62	68	follow
O	68	69	-
O	69	71	up
O	72	74	of
O	75	78	the
O	79	83	IBIS
O	83	84	-
O	84	85	I
O	86	92	breast
O	93	99	cancer
O	100	110	prevention
O	111	116	trial
O	116	117	.

O	118	122	Four
O	123	133	previously
O	134	143	published
O	144	154	randomised
O	155	163	clinical
O	164	170	trials
O	171	175	have
O	176	181	shown
O	182	186	that
O	187	196	tamoxifen
O	197	200	can
O	201	207	reduce
O	208	211	the
O	212	216	risk
O	217	219	of
O	220	226	breast
O	227	233	cancer
O	234	236	in
O	237	244	healthy
O	245	250	women
O	251	253	at
O	254	263	increased
O	264	268	risk
O	269	271	of
O	272	278	breast
O	279	285	cancer
O	286	288	in
O	289	292	the
O	293	298	first
O	299	301	10
O	302	307	years
O	308	310	of
O	311	317	follow
O	317	318	-
O	318	320	up
O	320	321	.

O	322	324	We
O	325	331	report
O	332	335	the
O	336	340	long
O	340	341	-
O	341	345	term
O	346	352	follow
O	352	353	-
O	353	355	up
O	356	358	of
O	359	362	the
O	363	367	IBIS
O	367	368	-
O	368	369	I
O	370	375	trial
O	375	376	,
O	377	379	in
O	380	385	which
O	386	389	the
O	390	402	participants
O	403	406	and
O	407	420	investigators
O	421	427	remain
O	428	435	largely
O	436	442	masked
O	443	445	to
O	446	455	treatment
O	456	466	allocation
O	466	467	.

O	468	470	In
O	471	474	the
O	475	479	IBIS
O	479	480	-
O	480	481	I
O	482	492	randomised
O	493	503	controlled
O	504	509	trial
O	509	510	,
B-eligibility	511	524	premenopausal
I-eligibility	525	528	and
I-eligibility	529	543	postmenopausal
I-eligibility	544	549	women
B-age	550	552	35
I-age	552	553	-
I-age	553	555	70
I-age	556	561	years
O	562	564	of
O	565	568	age
B-eligibility	569	575	deemed
I-eligibility	576	578	to
I-eligibility	579	581	be
I-eligibility	582	584	at
I-eligibility	585	587	an
I-eligibility	588	597	increased
I-eligibility	598	602	risk
I-eligibility	603	605	of
I-eligibility	606	616	developing
I-eligibility	617	623	breast
I-eligibility	624	630	cancer
O	631	635	were
O	636	644	randomly
O	645	653	assigned
O	654	655	(
O	655	656	1
O	656	657	:
O	657	658	1
O	658	659	)
O	660	662	to
O	663	670	receive
O	671	675	oral
O	676	685	tamoxifen
O	686	688	20
O	689	691	mg
O	692	697	daily
O	698	700	or
O	701	709	matching
B-control	710	717	placebo
O	718	721	for
O	722	723	5
O	724	729	years
O	729	730	.

O	731	739	Patients
O	740	744	were
O	745	753	randomly
O	754	762	assigned
O	763	765	to
O	766	769	the
O	770	773	two
O	774	783	treatment
O	784	790	groups
O	791	793	by
O	794	803	telephone
O	804	806	or
O	807	810	fax
O	811	820	according
O	821	823	to
O	824	825	a
O	826	831	block
O	832	845	randomisation
O	846	854	schedule
O	855	856	(
O	856	864	permuted
O	865	870	block
O	871	876	sizes
O	877	879	of
O	880	883	six
O	884	886	or
O	887	890	ten
O	890	891	)
O	891	892	.

O	893	901	Patients
O	902	905	and
O	906	919	investigators
O	920	924	were
O	925	931	masked
O	932	934	to
O	935	944	treatment
O	945	955	assignment
O	956	958	by
O	959	962	use
O	963	965	of
O	966	973	central
O	974	987	randomisation
O	988	991	and
O	992	997	coded
O	998	1002	drug
O	1003	1009	supply
O	1009	1010	.

O	1011	1014	The
O	1015	1022	primary
O	1023	1031	endpoint
O	1032	1035	was
O	1036	1039	the
B-outcome-Measure	1040	1050	occurrence
I-outcome-Measure	1051	1053	of
I-outcome-Measure	1054	1060	breast
I-outcome-Measure	1061	1067	cancer
I-outcome-Measure	1068	1069	(
I-outcome-Measure	1069	1077	invasive
I-outcome-Measure	1078	1084	breast
I-outcome-Measure	1085	1091	cancer
I-outcome-Measure	1092	1095	and
I-outcome-Measure	1096	1102	ductal
I-outcome-Measure	1103	1112	carcinoma
I-outcome-Measure	1113	1115	in
I-outcome-Measure	1116	1120	situ
I-outcome-Measure	1120	1121	)
O	1121	1122	,
O	1123	1131	analysed
O	1132	1134	by
O	1135	1144	intention
O	1145	1147	to
O	1148	1153	treat
O	1153	1154	.

O	1155	1158	Cox
O	1159	1171	proportional
O	1172	1178	hazard
O	1179	1185	models
O	1186	1190	were
O	1191	1195	used
O	1196	1198	to
O	1199	1205	assess
O	1206	1212	breast
O	1213	1219	cancer
O	1220	1230	occurrence
O	1231	1234	and
O	1235	1244	mortality
O	1244	1245	.

O	1246	1249	The
O	1250	1255	trial
O	1256	1258	is
O	1259	1265	closed
O	1266	1268	to
O	1269	1280	recruitment
O	1281	1284	and
O	1285	1291	active
O	1292	1301	treatment
O	1302	1304	is
O	1305	1314	completed
O	1314	1315	,
O	1316	1319	but
O	1320	1324	long
O	1324	1325	-
O	1325	1329	term
O	1330	1336	follow
O	1336	1337	-
O	1337	1339	up
O	1340	1342	is
O	1343	1350	ongoing
O	1350	1351	.

O	1352	1356	This
O	1357	1362	trial
O	1363	1365	is
O	1366	1376	registered
O	1377	1381	with
O	1382	1398	controlledtrials
O	1398	1399	.
O	1399	1402	com
O	1402	1403	,
O	1404	1410	number
O	1411	1425	ISRCTN91879928
O	1425	1426	.

O	1427	1434	Between
O	1435	1440	April
O	1441	1443	14
O	1443	1444	,
O	1445	1449	1992
O	1449	1450	,
O	1451	1454	and
O	1455	1460	March
O	1461	1463	30
O	1463	1464	,
O	1465	1469	2001
O	1469	1470	,
B-total-participants	1471	1475	7154
O	1476	1484	eligible
O	1485	1490	women
O	1491	1500	recruited
O	1501	1505	from
O	1506	1514	genetics
O	1515	1522	clinics
O	1523	1526	and
O	1527	1533	breast
O	1534	1538	care
O	1539	1546	clinics
O	1547	1549	in
O	1550	1555	eight
O	1556	1565	countries
O	1566	1570	were
O	1571	1579	enrolled
O	1580	1584	into
O	1585	1588	the
O	1589	1593	IBIS
O	1593	1594	-
O	1594	1595	I
O	1596	1601	trial
O	1602	1605	and
O	1606	1610	were
O	1611	1619	randomly
O	1620	1629	allocated
O	1630	1632	to
O	1633	1636	the
O	1637	1640	two
O	1641	1650	treatment
O	1651	1657	groups
O	1657	1658	:
B-intervention-participants	1659	1663	3579
O	1664	1666	to
O	1667	1676	tamoxifen
O	1677	1680	and
B-control-participants	1681	1685	3575
O	1686	1688	to
O	1689	1696	placebo
O	1696	1697	.

O	1698	1703	After
O	1704	1705	a
O	1706	1712	median
O	1713	1719	follow
O	1720	1722	up
O	1723	1725	of
O	1726	1728	16
O	1728	1729	.
O	1729	1730	0
O	1731	1736	years
O	1737	1738	(
O	1738	1741	IQR
O	1742	1744	14
O	1744	1745	.
O	1745	1746	1
O	1746	1747	-
O	1747	1749	17
O	1749	1750	.
O	1750	1751	6
O	1751	1752	)
O	1752	1753	,
O	1754	1757	601
B-outcome	1758	1764	breast
I-outcome	1765	1772	cancers
O	1773	1777	have
O	1778	1782	been
O	1783	1791	reported
O	1792	1793	(
B-iv-bin-abs	1793	1796	251
O	1797	1798	[
B-iv-bin-percent	1798	1799	7
I-iv-bin-percent	1799	1800	.
I-iv-bin-percent	1800	1801	0
I-iv-bin-percent	1801	1802	%
O	1802	1803	]
O	1804	1806	in
B-intervention-participants	1807	1811	3579
O	1812	1820	patients
O	1821	1823	in
O	1824	1827	the
O	1828	1837	tamoxifen
O	1838	1843	group
O	1844	1846	vs
B-cv-bin-abs	1847	1850	350
O	1851	1852	[
B-cv-bin-percent	1852	1853	9
I-cv-bin-percent	1853	1854	.
I-cv-bin-percent	1854	1855	8
I-cv-bin-percent	1855	1856	%
O	1856	1857	]
O	1858	1860	in
B-control-participants	1861	1865	3575
O	1866	1871	women
O	1872	1874	in
O	1875	1878	the
O	1879	1886	placebo
O	1887	1892	group
O	1892	1893	;
O	1894	1900	hazard
O	1901	1906	ratio
O	1907	1908	[
O	1908	1910	HR
O	1910	1911	]
O	1912	1913	0
O	1913	1914	.
O	1914	1916	71
O	1917	1918	[
O	1918	1920	95
O	1920	1921	%
O	1922	1924	CI
O	1925	1926	0
O	1926	1927	.
O	1927	1929	60
O	1929	1930	-
O	1930	1931	0
O	1931	1932	.
O	1932	1934	83
O	1934	1935	]
O	1935	1936	,
O	1937	1938	p
O	1938	1939	<
O	1939	1940	0
O	1940	1941	.
O	1941	1945	0001
O	1945	1946	)
O	1946	1947	.

O	1948	1951	The
B-outcome	1952	1956	risk
I-outcome	1957	1959	of
I-outcome	1960	1970	developing
I-outcome	1971	1977	breast
I-outcome	1978	1984	cancer
O	1985	1988	was
O	1989	1996	similar
O	1997	2004	between
B-outcome	2005	2010	years
I-outcome	2011	2012	0
I-outcome	2012	2013	-
I-outcome	2013	2015	10
O	2016	2017	(
B-cv-bin-abs	2017	2020	226
O	2021	2022	[
B-cv-bin-percent	2022	2023	6
I-cv-bin-percent	2023	2024	.
I-cv-bin-percent	2024	2025	3
I-cv-bin-percent	2025	2026	%
O	2026	2027	]
O	2028	2030	in
B-control-participants	2031	2035	3575
O	2036	2041	women
O	2042	2044	in
O	2045	2048	the
O	2049	2056	placebo
O	2057	2062	group
O	2063	2065	vs
B-iv-bin-abs	2066	2069	163
O	2070	2071	[
B-iv-bin-percent	2071	2072	4
I-iv-bin-percent	2072	2073	.
I-iv-bin-percent	2073	2074	6
I-iv-bin-percent	2074	2075	%
O	2075	2076	]
O	2077	2079	in
B-intervention-participants	2080	2084	3579
O	2085	2090	women
O	2091	2093	in
O	2094	2097	the
O	2098	2107	tamoxifen
O	2108	2113	group
O	2113	2114	;
O	2115	2121	hazard
O	2122	2127	ratio
O	2128	2129	[
O	2129	2131	HR
O	2131	2132	]
O	2133	2134	0
O	2134	2135	.
O	2135	2137	72
O	2138	2139	[
O	2139	2141	95
O	2141	2142	%
O	2143	2145	CI
O	2146	2147	0
O	2147	2148	.
O	2148	2150	59
O	2150	2151	-
O	2151	2152	0
O	2152	2153	.
O	2153	2155	88
O	2155	2156	]
O	2156	2157	,
O	2158	2159	p
O	2159	2160	=
O	2160	2161	0
O	2161	2162	.
O	2162	2165	001
O	2165	2166	)
O	2167	2170	and
B-outcome	2171	2176	after
I-outcome	2177	2179	10
I-outcome	2180	2185	years
O	2186	2187	(
B-cv-bin-abs	2187	2190	124
O	2191	2192	[
B-cv-bin-percent	2192	2193	3
I-cv-bin-percent	2193	2194	.
I-cv-bin-percent	2194	2195	8
I-cv-bin-percent	2195	2196	%
O	2196	2197	]
O	2198	2200	in
B-control-participants	2201	2205	3295
O	2206	2211	women
O	2212	2214	vs
B-iv-bin-abs	2215	2217	88
O	2218	2219	[
B-iv-bin-percent	2219	2220	2
I-iv-bin-percent	2220	2221	.
I-iv-bin-percent	2221	2222	6
I-iv-bin-percent	2222	2223	%
O	2223	2224	]
O	2225	2227	in
B-intervention-participants	2228	2232	3343
O	2232	2233	,
O	2234	2246	respectively
O	2246	2247	;
O	2248	2250	HR
O	2251	2252	0
O	2252	2253	.
O	2253	2255	69
O	2256	2257	[
O	2257	2258	0
O	2258	2259	.
O	2259	2261	53
O	2261	2262	-
O	2262	2263	0
O	2263	2264	.
O	2264	2266	91
O	2266	2267	]
O	2267	2268	,
O	2269	2270	p
O	2270	2271	=
O	2271	2272	0
O	2272	2273	.
O	2273	2276	009
O	2276	2277	)
O	2277	2278	.

O	2279	2282	The
O	2283	2291	greatest
O	2292	2301	reduction
O	2302	2304	in
O	2305	2309	risk
O	2310	2313	was
O	2314	2318	seen
O	2319	2321	in
B-outcome	2322	2330	invasive
I-outcome	2331	2340	oestrogen
I-outcome	2341	2349	receptor
I-outcome	2349	2350	-
I-outcome	2350	2358	positive
I-outcome	2359	2365	breast
I-outcome	2366	2372	cancer
O	2373	2374	(
O	2374	2376	HR
O	2377	2378	0
O	2378	2379	.
O	2379	2381	66
O	2382	2383	[
O	2383	2385	95
O	2385	2386	%
O	2387	2389	CI
O	2390	2391	0
O	2391	2392	.
O	2392	2394	54
O	2394	2395	-
O	2395	2396	0
O	2396	2397	.
O	2397	2399	81
O	2399	2400	]
O	2400	2401	,
O	2402	2403	p
O	2403	2404	<
O	2404	2405	0
O	2405	2406	.
O	2406	2410	0001
O	2410	2411	)
O	2412	2415	and
B-outcome	2416	2422	ductal
I-outcome	2423	2432	carcinoma
I-outcome	2433	2435	in
I-outcome	2436	2440	situ
O	2441	2442	(
O	2442	2443	0
O	2443	2444	.
O	2444	2446	65
O	2447	2448	[
O	2448	2449	0
O	2449	2450	.
O	2450	2452	43
O	2452	2453	-
O	2453	2454	1
O	2454	2455	.
O	2455	2457	00
O	2457	2458	]
O	2458	2459	,
O	2460	2461	p
O	2461	2462	=
O	2462	2463	0
O	2463	2464	.
O	2464	2466	05
O	2466	2467	)
O	2467	2468	,
O	2469	2472	but
O	2473	2475	no
O	2476	2482	effect
O	2483	2486	was
O	2487	2492	noted
O	2493	2496	for
B-outcome	2497	2505	invasive
I-outcome	2506	2515	oestrogen
I-outcome	2516	2524	receptor
I-outcome	2524	2525	-
I-outcome	2525	2533	negative
I-outcome	2534	2540	breast
I-outcome	2541	2547	cancer
O	2548	2549	(
O	2549	2551	HR
O	2552	2553	1
O	2553	2554	.
O	2554	2556	05
O	2557	2558	[
O	2558	2560	95
O	2560	2561	%
O	2562	2564	CI
O	2565	2566	0
O	2566	2567	.
O	2567	2569	71
O	2569	2570	-
O	2570	2571	1
O	2571	2572	.
O	2572	2574	57
O	2574	2575	]
O	2575	2576	,
O	2577	2578	p
O	2578	2579	=
O	2579	2580	0
O	2580	2581	.
O	2581	2582	8
O	2582	2583	)
O	2583	2584	.

O	2585	2590	These
O	2591	2598	results
O	2599	2603	show
O	2604	2608	that
O	2609	2618	tamoxifen
O	2619	2625	offers
O	2626	2627	a
O	2628	2632	very
O	2633	2637	long
O	2638	2644	period
O	2645	2647	of
O	2648	2658	protection
O	2659	2664	after
O	2665	2674	treatment
O	2675	2684	cessation
O	2684	2685	,
O	2686	2689	and
O	2690	2694	thus
O	2695	2708	substantially
O	2709	2717	improves
O	2718	2721	the
O	2722	2729	benefit
O	2729	2730	-
O	2730	2732	to
O	2732	2733	-
O	2733	2737	harm
O	2738	2743	ratio
O	2744	2746	of
O	2747	2750	the
O	2751	2755	drug
O	2756	2759	for
O	2760	2766	breast
O	2767	2773	cancer
O	2774	2784	prevention
O	2784	2785	.

O	2786	2792	Cancer
O	2793	2801	Research
O	2802	2804	UK
O	2805	2806	(
O	2806	2808	UK
O	2808	2809	)
O	2810	2813	and
O	2814	2817	the
O	2818	2826	National
O	2827	2833	Health
O	2834	2837	and
O	2838	2845	Medical
O	2846	2854	Research
O	2855	2862	Council
O	2863	2864	(
O	2864	2873	Australia
O	2873	2874	)
O	2874	2875	.
